WO2012141373A1 - Marqueur xage-1a pour une détection précoce du cancer du poumon et son utilisation - Google Patents

Marqueur xage-1a pour une détection précoce du cancer du poumon et son utilisation Download PDF

Info

Publication number
WO2012141373A1
WO2012141373A1 PCT/KR2011/003309 KR2011003309W WO2012141373A1 WO 2012141373 A1 WO2012141373 A1 WO 2012141373A1 KR 2011003309 W KR2011003309 W KR 2011003309W WO 2012141373 A1 WO2012141373 A1 WO 2012141373A1
Authority
WO
WIPO (PCT)
Prior art keywords
xage
lung cancer
protein
antibody
early diagnosis
Prior art date
Application number
PCT/KR2011/003309
Other languages
English (en)
Korean (ko)
Inventor
박성섭
김선영
하종성
권기선
김학균
정봉현
정용원
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2012141373A1 publication Critical patent/WO2012141373A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Definitions

  • the present invention relates to an XAGE-1a marker for early diagnosis of lung cancer and its use, and more particularly, a composition for early diagnosis of lung cancer, kit for early diagnosis of lung cancer, and microarray for early diagnosis of lung cancer comprising an antibody specifically binding to XAGE-1a protein.
  • the present invention relates to a method for diagnosing lung cancer by measuring the expression level of Xage-1a in a blood sample derived from the same.
  • lung cancer was the second largest cancer in Korea between 2003 and 2005, accounting for 12.1% of all cancers, and the incidence rate per 100,000 population was 33.2 cases.
  • the sex ratio of males and females was 3.83: 1, which occurred more frequently in males, and the number of occurrences was second in male cancers and fifth in female cancers.
  • the 60s were the highest with 34.3%, followed by the 70s with 31.0% and the 50s with 14.6%.
  • lung cancer is rapidly growing in Korea due to the increase of smoking population and air pollution.
  • the mortality rate of cancer is 1st with 21.4%
  • the mortality rate of men and women is 1st and 2nd with 24.9% and 15.1%, respectively. .
  • Lung cancer usually causes symptoms such as surrounding tissue involvement or airway obstruction and lymph node metastasis due to the growth of cancer cells, but in about 10 to 15% of patients, lung cancer is diagnosed at regular checkups without any symptoms. In addition, since most lung cancers are in a fairly advanced state at the time of diagnosis, there is a problem that most cases are difficult to cure. Therefore, it is urgent to diagnose lung cancer early and reduce mortality from lung cancer (Wulfkuhle et al., Nat. Rev. Cancer 3, 267-275, 2003).
  • CEA cancerembryionic antigen
  • CYFRA 21-1 cytokeratin 19 fragment
  • the inventors have discovered proteins that increase expression in lung cancer cells, and newly discovered that XAGE-1d protein is specifically present in the blood of patients with lung cancer.
  • PCT was applied by confirming that lung cancer can be easily diagnosed by immunochemistry through the detection of XAGE-1d (PCT / KR2010 / 003710).
  • the XAGE-1a of the present invention was originally known as XAGE-1b, but the existing XAGE-1a (146 amino acids) disappeared from the record and instead is a protein currently being recorded as XAGE-1a.
  • the XAGE-1a of the present invention is clearly distinguished from XAGE-1d and also shows high expression in the blood of lung cancer patients to complete the present invention.
  • Korean Patent No. 10-0661931 discloses a method for diagnosing cancer by measuring a change in a sugar chain of transferrin
  • Korean Patent No. 10-0931997 discloses a method for diagnosing hepatocellular carcinoma using the KLK-6 gene.
  • the present invention was derived by the above-described needs, and the present inventors have completed the present invention by confirming that the concentration of XAGE-1a protein in the blood of early stage lung cancer patients is significantly increased.
  • the present invention provides a composition for the early diagnosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • the present invention also provides a kit for early diagnosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • the present invention also provides a microarray for the early diagnosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • the present invention also provides a method for detecting a blood marker XAGE-1a for early diagnosis of lung cancer using the XAGE-1a protein specific antibody.
  • the present invention also provides a composition for predicting prognosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • the present invention also provides a method for diagnosing lung cancer by measuring the expression level of Xage-1a in a blood sample derived from a subject.
  • the early diagnosis method of lung cancer using the XAGE-1a blood marker of the present invention collects samples from blood, so it is easier to implement and relatively less pain than other methods. It is also expected to be useful for lowering the mortality rate from lung cancer because it can specifically diagnose lung cancer at an early stage.
  • HEK293T kidney cell line (control)
  • A549, NCI-H460 and Hop-92 lung cancer cell line
  • MCF-7, MDA-MB-453 and T-47D breast cancer cell line.
  • Figure 2 shows the absorbance (A) according to the concentration of biotin-XAGE-1a peptide and the quantification standard curve (B) by antigen competition ELISA according to the concentration of XAGE-1a peptide.
  • B Absorbance value obtained by adding the XAGE-1a peptide to the biotin-XAGE-1a peptide
  • Bo Absorbance value only of the biotin-XAGE-1a peptide.
  • Figure 3 shows the binding of biotin-XAGE-1a peptides to the concentration of the XAGE-1a peptide.
  • Figure 4 shows the hourly concentration of XAGE-1a secreted in the media of lung and breast cancer cell lines.
  • Figure 5 shows the distribution of XAGE-1a (A) and control groups CEA (B) and CYFRA 21-1 (C) in normal and patient blood.
  • Figure 6 shows the ROC graph of XAGE-1a (A) and the control CEA (B) and CYFRA 21-1 (C).
  • the present invention provides a composition for the early diagnosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • diagnosis means identifying the presence or characteristic of a pathological condition.
  • diagnosis is to determine whether lung cancer has developed.
  • lung cancer marker XAGE-1a protein of the present invention was detected higher than other lung cancer diagnostic markers CEA and CYFRA 21-1 in the early stage of lung cancer, it may be more effective for early diagnosis of lung cancer.
  • the XAGE-1a protein may be XAGE-1a carboxyl terminal, but is not limited thereto.
  • the XAGE-1a carboxyl terminal may preferably be composed of the amino acid sequence of SEQ ID NO: 1 (CATWKVIC KSCISQTPGI NLDLGSGVKV KIIPKEEHCK MPEAGEEQPQ V), but is not limited thereto.
  • variants of such sequences are included within the scope of the present invention.
  • a variant is a sequence that has a functional characteristic similar to that of the amino acid sequence of SEQ ID NO: 1, although the amino acid sequence changes.
  • the XAGE-1a carboxyl terminal has at least 70%, more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% homology with the amino acid sequence of SEQ ID NO: 1 May comprise an amino acid sequence.
  • Antibodies that specifically bind to the XAGE-1a protein may specifically recognize only XAGE-1a.
  • the antibody may be preferably a detection labeling agent capable of generating a detectable signal, and the detection labeling agent may be an enzyme, a prosthetic molecule, a fluorescent material, a luminescent material, a bioluminescent material or a radioactive material, but It is not limited.
  • the lung cancer refers to a malignant tumor occurring in the lung, and may preferably be non-small cell lung cancer, but is not limited thereto.
  • the composition may further comprise a secondary antibody that recognizes an antibody that specifically binds to XAGE-1a protein, and the detection labeling agent may be bound to the secondary antibody.
  • the composition may further include a substrate and a reaction terminator capable of measuring enzymatic activity when the detection labeling agent is an enzyme.
  • examples of enzymes suitable as detection markers include horseradish peroxidase, acetylcholine esterase, peroxidase, alkaline phosphatase, ⁇ -D-galactosidase, glucose oxidase, malate dehydro Geneases, glucose-6-phosphate dehydrogenases, invertases, and the like;
  • suitable submolecular complexes include streptavidin / biotin or avidin / biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, phycoerythrin or picobiliprotein, and the like;
  • Examples of the luminescent material include luminol, isoleucinol or lucigenin and the like;
  • bioluminescent materials include luciferase, luciferin or aequorin; Examples of bio
  • antibody is a term known in the art and refers to a protein molecule that binds to a known antigen.
  • Antibodies used in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (eg, Fab or (Fab) 2 fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain Fv molecules, Chimeric antibodies and the like, but is not limited thereto.
  • Antibodies used in the present invention can be obtained by isolation from the serum of a mammal immunized with an immunogen (antigen).
  • the mammal may preferably be mouse, rabbit or goat, but is not limited thereto.
  • mammals used in the manufacture of antibodies may be preferentially selected from relatively large mammals with greater amounts of serum capable of separating more antibodies.
  • an immunogen When the mammal is injected with an immunogen, it stimulates B cells of the immune system to produce immunoglobulins (Ig, immunoglobulin) specific for the immunogen.
  • the immunoglobulins can be purified from serum using methods known in the art such as filtration, dialysis, ion exchange chromatography, size exclusion chromatography or affinity chromatography.
  • an adjuvant such as Freund's, Alum, the Ribi Adjuvant System or Titermax may be injected for the purpose of enhancing the mammalian immune response to the injected immunogen.
  • the adjuvant enhances antigenicity when mixed with the antigen and helps to generate a lot of antibodies.
  • the present invention also provides a kit for early diagnosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • the XAGE-1a protein may be XAGE-1a carboxyl terminus, but is not limited thereto.
  • the kit may further comprise a secondary antibody that recognizes an antibody that specifically binds to XAGE-1a protein, and the detection labeling agent may be bound to the secondary antibody.
  • the kit may include an antibody specifically binding to the XAGE-1a protein according to the present invention, a suitable carrier solution, a detection label capable of generating a detectable signal, a dissolving agent, a container containing a cleaning agent, and instructions for use.
  • the kit may include a substrate and a reaction terminator capable of measuring enzymatic activity when the detection labeling agent is an enzyme.
  • the present invention also provides a microarray for the early diagnosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • the XAGE-1a protein may be XAGE-1a carboxyl terminus, but is not limited thereto.
  • the microarray can detect a protein that specifically attaches to the antibody by antigen-antibody reaction by attaching an antibody that specifically binds to XAGE-1a protein on a slide glass surface treated with a specific reagent.
  • It provides a method for detecting a blood marker XAGE-1a for the early diagnosis of lung cancer comprising the step of detecting the antigen-antibody complex.
  • the XAGE-1a protein may be XAGE-1a carboxyl terminus, but is not limited thereto.
  • the XAGE-1a carboxyl terminal may be composed of the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.
  • the method for detecting the antigen-antibody complex may be, but is not limited to, immunoblot, enzyme immunoassay, immunoprecipitation, fluorescence immunoassay, enzyme substrate coloration, or antigen antibody aggregation.
  • the present invention also provides a composition for predicting prognosis of lung cancer comprising an antibody that specifically binds to XAGE-1a protein.
  • Antibodies that specifically bind to the XAGE-1a protein of the present invention can be used not only for the early diagnosis of lung cancer, but also for the prognosis of lung cancer patients.
  • step b) comparing the expression level of Xage-1a in step a) with the expression level of Xage-1a in the normal blood sample;
  • c) providing a method for diagnosing lung cancer comprising determining that the subject's Xage-1a expression level is higher than that of a normal control group, and thus, the risk of developing lung cancer is high.
  • the subject of step a) is a vertebrate, including a human, preferably a mammal, more preferably a human, ape, bovine, pig, rat, rabbit, guinea peak, hamster, dog or Cats can be used, but are not limited thereto.
  • the expression level of Xage-1a is expressed by Western blotting, enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining, immunoprecipitation and immunity. It is preferable to measure by any one selected from the group consisting of fluorescence (immunofluorescence), but is not limited thereto.
  • XAGE1 was initially known as four transcription variants of a, b, c and d, but recently only two transcription variants with 81 amino acids and 69 amino acids have been identified (http: //www.ncbi. nlm.nih.gov/gene/653219?).
  • the present invention relates to a transcription variant XAGE-1a consisting of 81 amino acids, wherein the amino acid terminal has the same 32 amino acid sequence as that of XAGE-1d consisting of 69 amino acids, but differs from the other carboxyl terminal (Table 1).
  • the two proteins contain an underlined amino acid in common at the amino terminus.
  • each cell line was inoculated into 100 mm culture dishes to be 5 ⁇ 10 5 cells and incubated for 2 days, and then cells were recovered by trypsin treatment. After the recovered cells were lysed with RIPA buffer, 10 ⁇ g of protein was electrophoresed on a 15% polyacrylamide gel and transferred to nitrocellulose membrane. A chlorine antibody (Abcam, ab21198) specific for the carboxyl terminus (CPEAGEEQPQV) of XAGE-1a was added to the membrane and reacted with it. Protein was detected.
  • XAGE-1a In order to compare the expression of XAGE-1a with XAGE-1d, the expression of XAGE-1d was observed.
  • a goat antibody specific for the carboxyl terminus (GFGFRRQGEDNT) of XAGE-1d (Abcam, ab27477) was used.
  • the XAGE-1d protein (7.6 kD) showed similar expression in three lung and breast cancer cell lines except HEK293T kidney cells, whereas XAGE-1a (9 kD) was a lung cancer cell line NCI-H460 and breast cancer. Some less expression was observed in the cell line MCF-7 (FIG. 1).
  • a peptide (CPEAGEEQPQV) corresponding to the carboxyl terminus of XAGE-1a and a biotin-binding biotin-CPEAGEEQPQV (Peptron) were prepared to perform antigen competition ELISA. . After recognizing the peptide as a specific antibody, the amount of XAGE-1a in solution was sought by biotin: streptavidin binding and HRP reaction conjugated to streptavidin.
  • biotin-XAGE-1a peptide (biotin-CPEAGEEQPQV) specifically binds to the coated antibody, is also developed by STR-HRP bound to biotin, and the absorbance increases in proportion to the amount of biotin-peptide. It could be confirmed (FIG. 2A).
  • Antigen competition enzyme immunoassay was also performed using 4 ng / mL Biotin-XAGE-1a peptide. Instead of adding the biotin-XAGE-1a peptide in the experiment of FIG. 2A, absorbance was obtained by mixing XAGE-1a peptide of various concentrations in 100 ⁇ l of 40 ng / mL biotin-XAGE-1a peptide (biotin-CPEAGEEQPQV). Measured. Standard curves were calculated using B / Bo (B: absorbance value of XAGE-1a peptide added to Biotin-XAGE-1a peptide, Bo: absorbance value of only biotin-XAGE-1a peptide) for the concentration of XAGE-1a peptide.
  • the XAGE-1d peptide was found to be biotin- While XAGE-1a peptides did not inhibit binding to antibodies at all, XAGE-1a peptides inhibited the binding of biotin-XAGE-1a peptides in proportion to concentrations, and at about 10% binding at concentrations of 10 ng / mL Is shown (FIG. 3). The results show that ELISA with XAGE-1a specific antibody and biotin-XAGE-1a peptide will be able to detect XAGE-1a protein very specifically.
  • the antibody (ab21198, Abcam) that specifically binds to the carboxyl terminal CPEAGEEQPQV of XAGE-1a was dissolved in coating solution (1.59 g of Na 2 CO 3 , 2.93 g of NaHCO 3 and 2 mL of 10% NaN 3 , pH 9.5). 1 ⁇ g per well was coated on 96-well plates (Nunc # 439454) for 24 hours. To inhibit nonspecific binding, 200 ⁇ l of blocking solution per well (PBS with 0.1% BSA and 0.02% thimerosal) was treated at room temperature for 2 hours.
  • the wells were washed 5 times with washing solution (PBS containing 0.05% thimerosal and 0.05% Tween-20) and 100 ⁇ l of biotin-XAGE-1a peptide (40 ng / mL) per well and 100 ⁇ l of the cell line culture solution was added and mixed, followed by reaction at room temperature for 2 hours. After washing again with 200 ⁇ l of washing solution per well, HRP (horse radish peroxidase) bound streptavidin was added at a dilution of 1: 10,000 and bound for 2-3 hours.
  • washing solution PBS containing 0.05% thimerosal and 0.05% Tween-20
  • TMB substrate solution (GenDEPOT) was added to each well for peroxidase color development, followed by reaction at room temperature, and then 50 ⁇ l of stop solution (GenDEPOT) was added. Stop and absorbance at 465 nm wavelength was measured.
  • the absorbance value was substituted into the quantification standard curve equation, and the ratio of the molecular weight was calculated to determine the concentration of the XAGE-1a protein contained in the solution, and then expressed as a relative value of the total protein of the cells.
  • L549 cancer cell line A549 slowly secreted XAGE-1a over time, reaching 1 ng / ml ⁇ ⁇ g protein at 72 hours, whereas NCI-H460 cell line contained about 3 ng / mL ⁇ ⁇ g protein at the same time. Observed in the medium. Lung cancer cell line Hop-92 and three other breast cancer cell lines could not observe increased expression of XAGE-1a protein in the medium (FIG. 4).
  • CEA carcinoembryionic antigen, Accubind, # 1825-300
  • CYFRA 21-1 cytokeratin 19 fragment, Fujirebio, # 211-10) as controls were analyzed according to the manufacturer's assay kit manual.
  • XAGE-1a was about four times more present in lung cancer patients (average 11.7 ng / ml) than normal people (average 3.0 ng / ml), which is 1.4-1.5 times greater than CEA and CYFRA 21-1. The value was significantly higher, and maintained at over three times except for the thirties with a small number of samples. The sex ratio of males and females showed similar values, while XAGE-1a showed more than two times higher males than females in normal and patients (Table 2). The results show that XAGE-1a may be a better diagnostic marker than the well-known controls CEA and CYFRA 21-1 (Stieber et al. Cancer, 1993, 72 (3), 707-713).
  • Sensitivity and specificity of XAGE-1a were analyzed and compared with controls.
  • the maximum value of XAGE-1a was about 6 times the mean value, which is larger than 2 ⁇ 2.6 times of CEA and CYFRA 21-1.
  • the minimum value of XAGE-1a in lung cancer patients is very low.
  • the average value (3.03 ng / ml) of the normal person is very low, and the average value of lung cancer patients is about 4 times higher than that of the normal person, which is particularly distinguished from the control group.
  • Sensitivity is also slightly low, while specificity is very high compared to the control, especially CYFRA 21-1 (41.50 ng / ml), indicating that it may be a useful marker (Table 3).
  • XAGE-1a Median and interquartile ranges of XAGE-1a were 3.03 and 0.68 to 3.72 in normal subjects and 11.66 and 2.59 to 16.28 in lung cancer patients.
  • CEA was 10.35 and 7.95-12.40 in normal subjects and 16.81 and 13.10-20.83 in lung cancer patients.
  • CYFRA21-1 was 11.92 and 7.96 to 13.65 in normal subjects and 17.50 and 12.96 to 21.22 in lung cancer patients (FIG. 5).
  • Mann-Whitney U- test, p ⁇ 0.001 Mann-Whitney U- test, p ⁇ 0.001).
  • ROC curve analysis was performed based on the analysis results of XAGE-1a.
  • the area under the curve (AUC) was 0.787 for XAGE-1a, 0.815 for CEA, and 0.803 for CYFRA 21-1, and XAGE-1a showed similar values as the overall control (FIG. 6).
  • ROC curves were analyzed by dividing the samples according to the stage of tumor development.
  • XAGE-1a showed higher AUC than controls in IA ⁇ IIIA stages (Table 4). The results indicate that XAGE-1a can be used as a more effective diagnostic marker than the control in the early stages of lung cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une composition contenant des anticorps qui se lient spécifiquement à des protéines XAGE-1a pour la détection précoce du cancer du poumon, une trousse et un micro-réseau pour la détection précoce du cancer du poumon, un procédé de détection de marqueur sanguin XAGE-1a pour la détection précoce du cancer du poumon à l'aide des anticorps spécifiques à la protéine XAGE-1a, une composition contenant les anticorps qui se lient spécifiquement aux protéines XAGE-1a pour estimer le pronostic du cancer du poumon, et un procédé de diagnostic du cancer du poumon par mesure des quantités d'expression de XAGE-1a dans un échantillon sanguin provenant d'un sujet.
PCT/KR2011/003309 2011-04-11 2011-05-03 Marqueur xage-1a pour une détection précoce du cancer du poumon et son utilisation WO2012141373A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0033078 2011-04-11
KR1020110033078A KR20120116518A (ko) 2011-04-11 2011-04-11 폐암 조기 진단용 ＸＡＧＥ-1ａ 마커 및 이의 용도

Publications (1)

Publication Number Publication Date
WO2012141373A1 true WO2012141373A1 (fr) 2012-10-18

Family

ID=47009516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/003309 WO2012141373A1 (fr) 2011-04-11 2011-05-03 Marqueur xage-1a pour une détection précoce du cancer du poumon et son utilisation

Country Status (2)

Country Link
KR (1) KR20120116518A (fr)
WO (1) WO2012141373A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113687076A (zh) * 2021-07-14 2021-11-23 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
CN116482365A (zh) * 2023-03-14 2023-07-25 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102613772B1 (ko) * 2021-02-02 2023-12-14 제노마인(주) 폐암 혈액 바이오마커의 검출 방법 및 키트
WO2022169267A1 (fr) * 2021-02-02 2022-08-11 제노마인(주) Méthode et kit de détection d'un biomarqueur sanguin du cancer du poumon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
US20070202553A1 (en) * 2004-05-20 2007-08-30 Gang Zeng Dominant B Cell Epitopes and Methods of Making and Using Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202553A1 (en) * 2004-05-20 2007-08-30 Gang Zeng Dominant B Cell Epitopes and Methods of Making and Using Thereof
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALI MOHAMED ALI ELDIB ET AL.: "Immunoscreening of cDNA library from a lung cancer cell line using autologous patient serum: identification of XAGE-lb b as a dominant antigen and its immunogenicity in lung adenocarcinoma.", INT J CANCER., vol. 108, 2004, pages 558 - 563, XP055075155, DOI: doi:10.1002/ijc.11587 *
EIKI KIKUCHI ET AL.: "Prolonged survival of patients with lung adenocarcinoma expressing XAGE-lb and HLA class I antigens.", CANCER IMMUNITY., vol. 8, 2008, pages 1 - 6 *
KAZUHIKO NAKAGAWA ET AL.: "XAGE-1 expression in non-small cell lung cancer and antibody response in patients.", CLINICAL CANCER RESEARCH., vol. 11, no. 15, 2005, pages 5496 - 5503, XP008164200, DOI: doi:10.1158/1078-0432.CCR-05-0216 *
QUN LAI ET AL.: "Association of XAGE-1 Gene Expression with Clinical Characteristics of Lung Cancer.", CHINESE JOURNAL OF LUNG CANCER., vol. 13, no. 8, 2010, pages 786 - 789 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113687076A (zh) * 2021-07-14 2021-11-23 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
CN116482365A (zh) * 2023-03-14 2023-07-25 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用
CN116482365B (zh) * 2023-03-14 2023-10-20 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用

Also Published As

Publication number Publication date
KR20120116518A (ko) 2012-10-23

Similar Documents

Publication Publication Date Title
WO2017107974A1 (fr) Kit de test de détection de protéines sériques psmd4 ainsi que son procédé de détection et son application
WO2013133675A1 (fr) Ensembles de biomarqueurs multiples pour le diagnostic du cancer du sein, procédé de détection associé, et trousse de diagnostic du cancer du sein comprenant un anticorps dirigé contre ceux-ci
CN109142755B (zh) 一种诊断早期食管鳞状细胞癌的四种自身抗体联合检测试剂盒及应用
WO2010107158A1 (fr) Marqueur de diagnostic du cancer du sein comprenant de la thiérodoxine-1 comme ingrédient actif et trousse de diagnostic du cancer du sein utilisant ledit marqueur
WO2012091465A2 (fr) Anticorps monoclonaux contre l'amyloïde a du sérum, et cellules d'hybridome les produisant
CN113248609B (zh) 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
WO2012141373A1 (fr) Marqueur xage-1a pour une détection précoce du cancer du poumon et son utilisation
CN110187111B (zh) 一种用于早期贲门癌筛查elisa试剂盒
WO2016195051A1 (fr) Panel de biomarqueurs de plasma permettant le diagnostic du cancer du pancréas
WO2015174585A1 (fr) Kit comprenant un anticorps se liant spécifiquement à la protéine du facteur b du complément et anticorps se liant spécifiquement à la protéine d'antigène carbohydrate 19-9 pour le diagnostic du cancer du pancréas
CN111077312B (zh) 一组肿瘤相关抗原在制备贲门癌早期筛查试剂盒中的应用
WO2019022371A1 (fr) Composition pour le diagnostic du cancer colorectal, et méthode pour le diagnostic du cancer colorectal à l'aide de la composition
WO2015037907A1 (fr) Trousse et méthode de diagnostic, de pronostic ou de surveillance d'une maladie du foie par mesure de la quantité d'ast
WO2019013394A1 (fr) Anticorps monoclonal reconnaissant spécifiquement une protéine en2 ou composition pour le diagnostic du cancer de la prostate le contenant
WO2016175406A1 (fr) Procédé de diagnostic du syndrome de sjögren à l'aide du test de réactions anticorps, spécifique du syndrome de sjögren
KR101311717B1 (ko) 대장암 진단용 단백질 마커 멜라노트랜스페린 및 이에 대한 항체를 포함하는 대장암 진단 키트
US20100047830A1 (en) Compositions and methods for detecting cancers in a subject
WO2011129483A1 (fr) Marqueur xage-1d pour le diagnostic du cancer pulmonaire, et trousse de diagnostic utilisant un tel marqueur
KR101311718B1 (ko) 대장암 진단용 단백질 마커 ｒｐｅ-스폰딘 및 이에 대한 항체를 포함하는 대장암 진단 키트
US9435815B2 (en) Method for rapid detection of hepatocyte growth factor in biological fluids
WO2019022370A1 (fr) Composition pour le diagnostic du cancer gastrique et procédé de diagnostic du cancer gastrique à l'aide de cette dernière
WO2013002434A1 (fr) Marqueur contenant hpαr en tant que principe actif pour le diagnostic d'un cancer pulmonaire
CN111308090A (zh) 一种食管癌多联快速检测elisa试剂盒
WO2012077983A2 (fr) Composition de diagnostic du cancer de la vessie contenant ape1/ref-1 et kit de diagnostic du cancer de la vessie l'utilisant
WO2023090553A1 (fr) Kit de diagnostic pour diagnostiquer un cancer colorectal à l'aide d'urine humaine comme échantillon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11863564

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11863564

Country of ref document: EP

Kind code of ref document: A1